Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
15
Recruiting, any sponsor type, condition "phenylketonuria"
By trial status
The same filters, counted in each status. Pick one to switch.
15 trials
Showing 1 to 15, recently updated first.
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07477691 · 12 participants (planned) · Start May 29, 2026 · Primary completion Sep 30, 2027
Drug: Pegvaliase; Methotrexate · For: Phenylketonuria
Sites: Los Angeles, California; Aurora, Colorado; Tampa, Florida · 12 sites in all
Agios Pharmaceuticals, Inc.Industry
NCT07241234 · 20 participants (planned) · Start Apr 17, 2026 · Primary completion Jan 17, 2028
Drug: AG-181 · For: Phenylketonuria
Sites: Indianapolis, Indiana; Pittsburgh, Pennsylvania; Dallas, Texas · 5 sites in all
- A Study of Sepiapterin in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
PTC TherapeuticsIndustry
NCT06302348 · 56 participants (planned) · Start Mar 4, 2024 · Primary completion Feb 28, 2031
Drug: Sepiapterin · For: Phenylketonuria
Sites: Indianapolis, Indiana; Nedlands, Australia; North Adelaide, Australia · 14 sites in all
- A Study of MZE782 in Adults With PKURecruiting
Maze TherapeuticsIndustry
NCT07694440 · 38 participants (planned) · Start Jun 23, 2026 · Primary completion Dec 2027
Drug: MZE782; MZE782 · For: Phenylketonuria (PKU)
Sites: Oakland, California; Palo Alto, California; Chicago, Illinois · 9 sites in all
- A Study of JNT-517 in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06971731 · 120 participants (planned) · Start Oct 20, 2025 · Primary completion Mar 1, 2028
Drug: JNT-517; JNT-517 Matching Placebo · For: Phenylketonuria
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 26 sites in all
Birmingham Women's and Children's NHS Foundation TrustAcademic, hospital or other
NCT07728032 · 148 participants (planned) · Start Oct 1, 2025 · Primary completion Dec 2026
Drug: Sapropterin Dihydrochloride; Sepiapterin · For: Phenylketonuria
Sites: Birmingham, United Kingdom
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07446400 · 48 participants (planned) · Start Mar 31, 2026 · Primary completion Nov 7, 2026
Drug: Repinatrabit; EE/NE and 4 more · For: Healthy Volunteers
Sites: Melbourne, Australia
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07713758 · 32 participants (planned) · Start Jul 17, 2026 · Primary completion Feb 9, 2027
Drug: Repinatrabit · For: Phenylketonuria
Sites: Miami, Florida
- GenSci144 Tablets Phase I Clinical TrialRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07685210 · 48 participants (planned) · Start Jun 22, 2026 · Primary completion Sep 2026
Drug: GenSci144 tablets; GenSci144 placebo tablets · For: Phenylketonuria
Sites: Jinan, China
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT07672756 · 48 participants (planned) · Start Jul 20, 2025 · Primary completion Jun 1, 2027
Drug: PL54 · For: Phenylketonuria (PKU)
Sites: Hefei, China
- A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06628128 · 240 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 1, 2027
Drug: JNT-517 · For: Phenylketonuria (PKU)
Sites: Gainesville, Florida; Tampa, Florida; Portland, Oregon · 12 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT05813678 · 450 participants (planned) · Start Jun 6, 2022 · Primary completion Nov 1, 2033
Drug: Pegvaliase · For: Phenylketonuria (PKU)
Sites: Aurora, Colorado; Atlanta, Georgia; Chicago, Illinois · 26 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06305234 · 200 participants (planned) · Start Jan 20, 2024 · Primary completion Nov 18, 2033
Drug: Pegvaliase · For: Phenylketonuria (PKU)
Sites: Aurora, Colorado; Atlanta, Georgia; Chicago, Illinois · 11 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT05579548 · 50 participants (planned) · Start Nov 22, 2022 · Primary completion Oct 4, 2032
Drug: Pegvaliase · For: Phenylketonuria, Maternal
Sites: Wilmington, North Carolina; Calgary, Canada; Hamburg, Germany · 4 sites in all
Emory UniversityAcademic, hospital or other
NCT04404530 · 45 participants (planned) · Start Oct 8, 2019 · Primary completion Dec 2028
Drug: Palynziq · For: Phenylketonurias
Sites: Atlanta, Georgia · 2 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.